Lin BioScience, Inc. (TPEX:6696)

Taiwan flag Taiwan · Delayed Price · Currency is TWD
366.00
-8.00 (-2.14%)
At close: Jan 9, 2026
177.27%
Market Cap30.28B
Revenue (ttm)n/a
Net Income (ttm)-1.02B
Shares Out82.73M
EPS (ttm)-12.79
PE Ration/a
Forward PEn/a
Dividendn/a
Ex-Dividend Daten/a
Volume626,182
Average Volume632,752
Open372.50
Previous Close374.00
Day's Range359.50 - 377.50
52-Week Range91.50 - 502.00
Beta0.04
RSI41.58
Earnings DateApr 26, 2026

About Lin BioScience

Lin BioScience, Inc., a drug development company, develops therapies for oncology, ophthalmology, and metabolic diseases. Its product pipeline includes LBS-008, an oral therapy for dry age-related macular degeneration (Dry AMD)and stargardt diseases (STGD1), which is under Phase 3 clinical trial to evaluate safety and efficacy in adolescent STGD1 and under phase 2 or phase 3 clinical trial to evaluate safety and efficacy in Dry AMD; LBS-007, a natural non-ATP CDC7 inhibitor for the treatment of cancers; LBS-002, an anti-tubulin to treat primary... [Read more]

Industry Biotechnology
Sector Healthcare
CEO Zhengqi Wang
Country Taiwan
Stock Exchange Taipei Exchange
Ticker Symbol 6696
Full Company Profile

Financial Performance

Financial Statements

News

There is no news available yet.